

WHEN THE WORLD IS COUNTING ON YOU, COUNT ON SIGNANT TO HELP DELIVER YOUR VACCINE

We know vaccine studies can be large, multinational endeavors with sensitive timeframes, extended participant follow up periods, multiphase designs, and critical data management needs. Leverage SmartSignals to navigate these challenges and gather the audit-ready, high quality evidence you need to get your vaccine to the public:



eCOA

Use our built-in reactogenicity diary instrument on either provisioned or bring-your-own devices to collect high quality primary safety data. Flexible implementation options, built-in alerts that keep PROs on track, and data management services are just some of the features that make our eCOA solution ideal for vaccine studies.



eCONSENT

Rapidly implement one of our three eConsent options to remotely obtain informed consent and re-consent while maintaining traceable audit trail.



TELEMEDICINE

Connect participants to study teams to improve safety and reduce unnecessary site visits.



RTSM

Optimize study supply management and efficiently manage mid-study changes using adaptable randomization and distribution schemes as well as our global logistics team that can handle any product's time or temperature requirements.




PATIENT CONCIERGE

Keep participants engaged during long follow-up periods, encouraging study requirements adherence and participant retention.

When Pfizer requested our services for a rapidly implemented phase I/II/III trial, Signant facilitated the launch of a 44,000-participant, global vaccine study involving 150 sites in seven countries — in just five weeks. Signant was the only partner prepared with the solutions, global reach, and resources to meet the protocol’s challenges, helping the sponsor achieve Emergency Use Authorization in record time.

REIMAGINE THE PATH TO PROOF WITH SIGNANT HEALTH.

PAST 5 YEARS OF VACCINE eCOA EXPERIENCE



WHO IS SIGNANT HEALTH?

As the evidence generation company, Signant Health provides the solutions and expertise you need to validate vaccine safety and efficacy endpoints.

